ASCO GI 2023 Conference Coverage


 

ASCO GI 2023 Final Results of the Phase II RE-ExPEL Study: Ramucirumab Beyond Progression + TAS 102 in Advanced/Metastatic Adenocarcinoma of the Stomach or GEJ, After Treatment Failure on a Ramucirumab-Based Therapy

171 views
January 31, 2023
Comments 0
Login to view comments. Click here to Login